283 related articles for article (PubMed ID: 36908268)
1. Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer.
Yeh YS; Tsai HL; Chen PJ; Chen YC; Su WC; Chang TK; Huang CW; Wang JY
Expert Rev Mol Diagn; 2023 Mar; 23(3):231-241. PubMed ID: 36908268
[TBL] [Abstract][Full Text] [Related]
2. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
3. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
[TBL] [Abstract][Full Text] [Related]
5. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
6. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer.
Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G
Front Immunol; 2023; 14():1298524. PubMed ID: 38187388
[TBL] [Abstract][Full Text] [Related]
7. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability-Lessons from Colorectal Cancer.
Greco L; Rubbino F; Dal Buono A; Laghi L
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372349
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
10. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.
Jin Z; Sinicrope FA
J Clin Oncol; 2022 Aug; 40(24):2735-2750. PubMed ID: 35649217
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
Link JT; Overman MJ
Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
[TBL] [Abstract][Full Text] [Related]
12. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
Kreidieh M; Mukherji D; Temraz S; Shamseddine A
Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
14. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
[TBL] [Abstract][Full Text] [Related]
15. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
Tan E; Sahin IH
Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
[No Abstract] [Full Text] [Related]
16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
17. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer.
Sahin IH; Goyal S; Pumpalova Y; Sonbol MB; Das S; Haraldsdottir S; Ahn D; Ciombor KK; Chen Z; Draper A; Berlin J; Bekaii-Saab T; Lesinski GB; El-Rayes BF; Wu C
Oncologist; 2021 Aug; 26(8):668-675. PubMed ID: 33631043
[TBL] [Abstract][Full Text] [Related]
18. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective.
Liu N; Shan F; Ma M
Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
20. Application of immune checkpoint inhibitors in colorectal cancer.
Wang L; Huang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
